December 9th 2024
Despite the risks of sun exposure, a study found only a fraction of coaches receive adequate UV-related guidance from their associations or clubs.
21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
February 8, 2025
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
‘REEL’ Time Patient Counseling™: Fostering Effective Conversations in Practice to Create a Visible Impact for Patients Living with Genital Psoriasis
View More
Childhood skin disease has unique challenges
September 17th 2014Therapeutics is one of the most significant challenges in pediatric dermatology. Children have been identified as “therapeutic orphans”, with few options that have FDA-approved pediatric indications. Access to new and novel treatments like biologics is especially limited. Supportive legislation, beginning with the Best Pharmaceuticals for Children Act (bpca.nichd.nih.gov), has marked the dawn of a new era.
Researchers ID genetic alterations, shedding light on hereditary melanoma
August 18th 2014Identifications of mutations such as those that lie in the telomerase reverse transcriptase (TERT) promoter area are shedding light on hereditary melanoma, according to the Director of the Massachusetts General Hospital Melanoma and Pigmented Lesion Center and Professor of Dermatology at Harvard Medical School in Boston.
Latest updates on advanced BCC treatment research
August 13th 2014Advanced basal cell carcinoma (aBCC) is a term used to describe a subset of basal cell carcinomas (BCCs) that have extensive, invasive or metastatic involvement; are located near vital and sensitive areas; or are recurrent despite multiple treatments. The diagnosis of aBCC is dependent on many patient specific factors, some of which are subjective and may be open to interpretation by both the patient and provider.
Dermatopathology sits in healthcare reform crosshairs
August 11th 2014If dermatologists don’t more effectively police themselves, experts say, they may lose their ability to perform in-office dermatopathology. Dermatopathology also faces competitive pressures and aggressive fee reductions, these experts add.
Celebrate the community while strengthening your practice
July 16th 2014When was the last time you got really excited about dermatology? I mean, in your bones, core-shaking, vitality-restoring, conquer the universe type of elation. If the answer is “Well, I can’t remember the last time.” or worse yet, “Maybe never?” then perhaps it is time to throw a party.
The role of the dermatologist in diagnosing, managing advanced basal cell carcinoma
July 15th 2014Advanced basal cell carcinoma is a term whose frequency of usage has increased recently, in part, due to the introduction of the Hedgehog pathway inhibitor, vismodegib. Advanced basal cell carcinoma (aBCC) is comprised of two subtypes of BCC associated with significant morbidity and mortality, locally advanced BCC (laBCC) and metastatic BCC (metBCC).
Electronic brachytherapy allows collaboration between dermatologists, radiation oncologists
July 7th 2014Electronic surface brachytherapy allows dermatologists to offer patients another safe, effective option for nonmelanoma skin cancer (NMSC), many experts say. And if the specialty doesn’t seize the opportunity, they add, it might lose some skin cancer treatments to radiation oncologists.
Smoothened inhibitors provide new options for BCC treatment
June 17th 2014Since the dawn of smoothened inhibitors, patients with locally advanced and metastatic basal cell carcinoma (BCC) now have a new and effective treatment alternative beyond the traditional and less optimal treatment approaches such as surgery and radiotherapy.
Predictive risk hierarchy for NMSC recurrence guides treatment strategies
May 19th 2014A recent study suggests that the most important predictive factors of recurrence for nonmelanoma skin cancers (NMSC) following radiotherapy include immunosuppression, age of the patient, tumor size as well as the treatment modality used.